Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Depigoid Mite-Mix
- Development stage
- Unknown
- Lead developer
- Leti Pharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Depigoid Mite-Mix is a depigmented polymerized allergen extract developed by LETI Pharma for allergen-specific immunotherapy (AIT). It is indicated for the treatment of allergic rhinoconjunctivitis and controlled asthma caused by house dust mites, specifically a mixture of *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. The manufacturing process involves depigmentation to remove non-allergenic components and polymerization with glutaraldehyde. This modification significantly reduces the extract's IgE-binding capacity, thereby lowering the risk of systemic allergic reactions during treatment, while preserving the T-cell epitopes necessary to induce immunological tolerance. The therapy works by shifting the immune response from a Th2-mediated allergic profile toward a Th1 and regulatory T-cell (Treg) profile, leading to the production of protective IgG4 antibodies.
- Brand names
- DepigoidDepigoid Mite-MixDepigoid Ácaros Mix
- Other names
- Depigmented polymerized house dust mite allergen extractDepigmented polymerized extract of Dermatophagoides pteronyssinus and Dermatophagoides farinae
02
Targets
House dust mite allergen-specific B-cell receptors and antibodies
Beyond the preview
Go deeper on Depigoid Mite-Mix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Depigoid Mite-Mix.